A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin.
Molecular Weight
3367.9 Da
Half-Life
~30 minutes
Typical Dose
100–200 mcg
Cycle Length
8–16 weeks
Description
CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). The No DAC designation refers to the absence of a Drug Affinity Complex — a lysine-maleimide modification that, in the DAC version, allows the peptide to bind to albumin and dramatically extends its half-life. Without DAC, CJC-1295 has a half-life of approximately 30 minutes, closely mimicking the pulsatile nature of endogenous GHRH secretion. This physiological pulsatility is considered advantageous because it preserves the natural GH secretion pattern, reducing the risk of pituitary desensitization. It is almost universally combined with a GHRP such as Ipamorelin to achieve synergistic GH release through complementary receptor pathways.
Key Characteristics
Molecular FormulaC152H252N44O42
Molecular Weight3367.9 Da
Half-Life~30 minutes
Administration RoutesSubcutaneous injection
Typical Dose100–200 mcg
Frequency2–3x daily (with Ipamorelin)
Investigated Benefits
Physiological GH pulsatility
Improved body composition
Enhanced recovery
Better sleep quality
More natural GH pattern vs DAC version
* Benefits based on preclinical/animal research unless otherwise noted.
Peptide Protocol Education Portal
Members-Only Access
Access advanced peptide education, protocol insights, and research-based information curated for informed users. Create a free account or log in to continue.
Please acknowledge the disclaimer above to continue.